Physician profile
Caryn J Ecker
NPI 1427351063
$5,004.10
in general payments reported to CMS, 2019-2025
42 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $850 · 2023: $874 · 2024: $1,695 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,574.41 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $599.19 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Lilly USA, LLC | $351.54 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Janssen Biotech, INC. | $336.85 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Astellas Pharma US INC | $285.88 | 2021-2025 | Padcev, Vyloy |
| Pfizer INC. | $283.86 | 2022-2025 | |
| Abbvie INC. | $277.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $248.89 | 2021-2025 | Enhertu, Tagrisso, Lynparza |
| Genentech USA, INC. | $173.69 | 2023-2025 | Tecentriq, Venclexta, Alecensa |
| Eisai INC. | $169.62 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $168.39 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.82 | 2022-2024 | Fruzaqla, Ninlaro, Alunbrig |
| Rigel Pharmaceuticals, INC. | $152.52 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $149.52 | 2021-2025 | Opdivo, Krazati |
| Genzyme Corporation | $142.08 | 2021-2025 | |
| Incyte Corporation | $135.06 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.